Bioventus (BVS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting opened with a reminder about forward-looking statements and associated risks under U.S. Securities Laws.
Board members, executive officers, and the independent auditor were introduced at the start.
The agenda and rules of conduct were reviewed, including voting and Q&A procedures.
Board and executive committee updates
Board members and key executives, including the CEO, CFO, General Counsel, and VP of Investor Relations, were introduced.
Corporate governance
Paul Ramirez of Broadridge was appointed Inspector of Election and signed the customary oaths.
A quorum was confirmed, allowing the meeting to proceed with official business.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bioventus
- 2026 guidance targets $605M revenue, margin expansion, and growth from PNS, PRP, and global markets.BVS
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Q1 2026 saw 7% revenue growth, higher margins, and raised full-year earnings guidance.BVS
Q1 20266 May 2026 - Q4 2025 saw 10% organic growth, record cash flow, and strong 2026 growth guidance.BVS
Q4 20251 May 2026 - Vote on 12 director nominees and auditor ratification at the June 2026 virtual annual meeting.BVS
Proxy filing22 Apr 2026 - Shareholders to elect twelve directors and ratify auditor amid strong growth and governance focus.BVS
Proxy filing22 Apr 2026 - Strong growth, margin expansion, and cash flow drive value across a $6.4B market.BVS
Corporate presentation23 Mar 2026 - Q2 revenue up 10.3%, guidance raised, with $31.9M impairment and litigation settlement.BVS
Q2 20242 Feb 2026 - Accelerated growth, margin expansion, and debt reduction position for substantial value creation.BVS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 revenue up 15%, guidance raised, divestiture and litigation drive key financial changes.BVS
Q3 202416 Jan 2026